P < .001). The overall mortality rate was 28.0%. Of the variables examined, the strongest risk factor associated with mortality was hemopneumothorax (OR, 12.49; CI,; P ¼ .03), followed by inferior vena cava injury (OR, 12.05; CI, P ¼ .001; Fig).
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Objective: Thoracic outlet syndrome (TOS) results from compression of the neurovascular structures in the thoracic outlet. Decompression provides relief of TOS symptoms, but little is known about long-term function and quality of life (QoL) from a patient's perspective. The purpose of this study was to evaluate surgical and QoL outcomes after surgical decompression of the thoracic outlet using a paraclavicular approach.
Methods: We reviewed our prospectively maintained database of patients who underwent thoracic outlet decompression. Short-term outcomes were assessed by the Derkash classification using contingency table methods, and long-term outcomes including 12-Item Short Form Health Survey QoL were assessed by multiple regression. The 12-Item Short Form Health Survey was scored by published criteria, and scalespecific and aggregate mental and physical health-related QoL scores were computed. Aggregate QoL scores range from 0 (terrible) to 100 (perfect) and, for context, average 50 6 10 in the general population for this age group. Secondary outcomes included mortality, complications, and duration of hospital stay.
Results: Between August 2004 and August 2018, we performed 100 decompression procedures. Median age was 35 years (interquartile range, 24-47 years), and 58 (58%) were female. The mean duration of hospital stay was 4.48 days. The etiology of TOS was venous in 46, arterial in 8, neurogenic in 42, and mixed vascular and neurogenic in 4. Good or excellent Derkash results were reported in 77 (77%) patients (46/54 [85%] of those with vascular TOS vs 31/46 [67%] of those with neurogenic etiology; P < .036). Long-term QoL was obtained in 93 of 100 (93%), with a median duration from surgery of 6.1 (3.3-9.3) years. Patients with neurogenic TOS reported significantly lower aggregate mental health QoL than vascular TOS patients (57 vs 59; P < .016). This effect persisted across the entire duration of follow-up and was unaffected by time out from surgery (regression P for time ¼ .509). In contrast, aggregate physical function QoL was unaffected by neurogenic etiology (P ¼ .303), and all patients improved linearly with time (0.5 scale unit/y; P < .009). There were no deaths or injuries to the long thoracic nerve. Complications included pleural effusion or hemothorax requiring evacuation (n ¼ 6), phrenic nerve palsy (n ¼ 6), and lymph leak (n ¼ 2) treated with tube thoracostomy.
Conclusions: Neurogenic TOS is associated with significantly reduced short-term Derkash score. Patient-reported physical health QoL improves linearly with time from surgery regardless of etiology of TOS, whereas mental health QoL is severely affected in neurogenic TOS, and this effect does not improve over time.
Author Disclosures: Z. Al Rstum: Nothing to disclose; H. Sandhu: Nothing to disclose; C. Miller: Nothing to disclose; N. Saqib: Nothing to disclose; G. Martin: Nothing to disclose; J. Besho: Nothing to disclose; K. Charlton-Ouw: Nothing to disclose; A. Azizzadeh: Nothing to disclose. UA). Overall, CCAB had higher rates of stroke (2.6% vs 1.3%; P ¼ .002) and SDM (7.3% vs 3.5%; P < .001) but similar rates of MI (0.9% vs 1.6%; P ¼ .12) compared with ICEA. In SA, no difference was seen in stroke (1.2% for ICEA vs 1.9% for CCAB; P ¼ .36), MI (1.3% vs 1.4%; P ¼ .95), or SDM (2.9% vs 4.7%; P ¼ .13). In UA, no difference was seen in stroke (1.6% for ICEA vs 2.8% for CCAB; P ¼ .06), but ICEA had higher rates of MI (2.4% vs 0.7%; P ¼ .01) and CCAB had higher rates of SDM (5.5% vs 8.2%; P ¼ .01; Table) After logistic regression in the UA cohort, predictors of MI included ICEA (odds ratio [OR], 2.8; 95% confidence interval [CI], 1.1-7.1; P ¼ .03) and symptomatic status (OR, 2.0; 95% CI, 1.1-3.6; P ¼ .02); symptomatic status also predicted stroke (OR, 1.9; 95% CI, 1.04-3.6; P ¼ .04), but CCAB did not.
Conclusions: In patients with symptomatic CAD, both clinical CAD severity and operative strategy affect outcomes. In SA patients, CCAB does not increase perioperative morbidity. However, CCAB in UA patients prevents MI while not appreciably increasing stroke risk. This suggests that coronary revascularization before or concomitant with CEA should be considered in UA patients but that temporally prioritizing the treatment of one vascular bed over the other is less important in SA patients. 
